Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timolol for Acne and Rosacea
NCT02774590Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of timolol in acne vulgaris and rosacea, sponsored by Johns Hopkins University. Primary endpoints: Safety and tolerability of timolol for acne and rosacea as assessed by subject report at 8 weeks and Safety and tolerability of timolol for acne and rosacea as assessed by physician assessment at 8 weeks. Started Mar 2016; status: completed.
02
Drugs
timolol
03
Conditions
acne vulgarisrosacea
Beyond the preview
Go deeper on NCT02774590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02774590.